about
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable diseaseQuality of health information on the Internet in pediatric neuro-oncologyState of affairs in use of steroids in diffuse intrinsic pontine glioma: an international survey and a review of the literatureMutations of the BRAF gene in human cancer'I have to live with the decisions I make': laying a foundation for decision making for children with life-limiting conditions and life-threatening illnessesRecurrent activating ACVR1 mutations in diffuse intrinsic pontine gliomaMolecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug developmentSurvival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteriaDiffuse brainstem glioma in children: critical review of clinical trials.Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma.Phase I study of fotemustine in pediatric patients with refractory brain tumors.Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours.Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor studyA phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumorsMEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children.Microsatellite instability in pediatric high grade glioma is associated with genomic profile and differential target gene inactivation.Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult diseaseInnovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumorsEnhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.Central nervous system tumours in adolescents.Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey.Pediatric CNS tumors: current treatment and future directions.Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04).Natural history and outcome of optic pathway gliomas in children.Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem.Paediatric and adult malignant glioma: close relatives or distant cousins?Preclinical drug development for childhood cancer.A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study.Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia.Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN.MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature.What are the experiences of the child with a brain tumour and their parents?Clinical presentation and prognostic indicators in 100 adults and children with neurofibromatosis 1 associated non-optic pathway brain gliomas.
P50
Q24310764-D0082143-4C9D-470D-9CE5-1BEBCF1A461BQ24683739-02DBF6A7-B33E-47F4-933D-596F90E0BAF2Q26749591-F45B1D6D-61EB-47C6-9714-A26A6B8599A8Q27860760-F2CDA968-345A-49D7-99CA-0CF798382135Q28071339-88EA51B0-5C66-4E7C-AF2D-D4902AB1A103Q28237518-7A112C2D-85CA-4D8E-A428-771C7F8BB397Q28475285-7A144E04-4A27-47A3-B89B-D492FE616B88Q30829348-37948A5F-6AC6-4C09-91DF-D6C7BE805FC0Q31033307-F451AF4D-C23C-4E63-846D-5DA2976B436BQ31131768-55BE7E51-8C27-4243-B104-C5C52B94D4C1Q33344136-89D94BC3-6516-43E5-B35A-A81562EBEACAQ33372217-0BD80A30-2780-467F-8836-0281E794A8C2Q33409117-0C307E02-F120-4D5D-90F7-0725D964797FQ33418532-113B4258-E1E0-4C5D-B7E4-83C26BBF5BF3Q33435808-087CA41C-C0EC-4CBB-927B-AD505F049207Q33577613-12A79E06-EF3A-45D1-922D-F5CD8480F9D8Q33921162-F6956017-F281-42AA-9208-E300160A7F58Q33990951-1139B22A-3B63-4BE8-A29F-959A0329D31EQ34480582-3598E3F1-D71D-4476-87B2-FD7ED7978637Q35177853-C29B2972-D7D9-49C0-A336-E1E43055127BQ35595191-B5532E06-E4D0-45B9-A581-731BDB443293Q36010097-6019AD2D-6D8B-4803-8B05-405ED68073FCQ36705927-F90EBABF-D022-4229-BF91-A9E66E37E9FCQ36902043-6033CBB3-3B28-4595-A0FC-DC37691D7498Q37369556-D4A058AA-B447-4F40-BC39-2A72869FDDA6Q37557498-1F797FDB-C9F0-4E54-86DE-38536E10950EQ37564201-CB7ED368-C21F-4D39-8C24-91A93AA79795Q37763907-5E86C2F4-4BF7-4472-93CF-B8BECC68F7F5Q38013990-E44E37FB-C943-4463-8580-7F471D7585ABQ38014543-6B7A9A7C-E29E-4810-9276-9E502E745A0AQ38086448-41B2363E-7032-4305-817A-0C58C18F9CBAQ38233425-AD515D3E-5CD1-4A91-8103-99C5E2599E88Q38420153-B2FFEAA5-0B00-41DC-947D-7DF680045182Q38818290-CC9A24B1-3C8A-4DFC-B0B1-3C62E7A0299DQ38820593-018F7D59-6ECD-4FA3-B078-27FE2F13F90CQ38972542-2BACE018-2E10-41E5-9967-FB681148820BQ39173934-B28FB33F-F045-4A3A-BCB0-E21775796638Q39646080-F9B180C8-2A33-4751-9DB9-446208B3DA9FQ39981577-61165CAA-7768-4E57-895B-4C6BC8C750DAQ40167910-987121B8-C6FB-4323-8F28-9E364F3DD559
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Darren Hargrave
@ast
Darren Hargrave
@en
Darren Hargrave
@es
Darren Hargrave
@nl
Darren Hargrave
@sl
type
label
Darren Hargrave
@ast
Darren Hargrave
@en
Darren Hargrave
@es
Darren Hargrave
@nl
Darren Hargrave
@sl
prefLabel
Darren Hargrave
@ast
Darren Hargrave
@en
Darren Hargrave
@es
Darren Hargrave
@nl
Darren Hargrave
@sl
P1053
H-1066-2014
P106
P1153
6603846556
P21
P31
P3829
P496
0000-0001-8219-9807